Table 1.
Variable | Study Population | Clinical Trial Article (n = 191) |
Samples with Available RNA (n = 123) |
---|---|---|---|
Randomization arm | Cetuximab + cisplatin Cetuximab + cisplatin + paclitaxel |
100 (52%) 91 (48%) |
61 (50%) 62 (50%) |
Age (years) | Median Range |
63 33–83 |
62 33–83 |
Sex, n (%) | Female Male |
42 (22%) 149 (78%) |
27 (22%) 96 (78%) |
ECOG PS, n (%) | 0 1 |
97 (51%) 94 (49%) |
74 (60%) 49 (40%) |
Primary tumor site, n (%) | Oropharynx Other |
70 (37%) 121 (63%) |
49 (40%) 74 (60%) |
HPV, n (%) (oropharynx only) |
Not tested HPV-negative HPV-positive |
41 (59%) 16 (23%) 13 (19%) |
35 (71%) 6 (12%) 8 (16%) |
Site of recurrence, n (%) | Missing Local recurrence Locoregional recurrence Metastasis Metastasis/local/regional recurrence Regional recurrence |
3 (2%) 27 (14%) 42 (22%) 59 (31%) 49 (26%) 11 (6%) |
1 (1%) 14 (11%) 26 (21%) 37 (30%) 38 (31%) 7 (6%) |